Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;29(1):2357-2374.
doi: 10.1080/10717544.2022.2096712.

Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres

Affiliations

Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres

Alba Aragón-Navas et al. Drug Deliv. 2022 Dec.

Abstract

To create a chronic glaucoma animal model by a single intracameral injection of biodegradable poly lactic-co-glycolic acid (PLGA) microspheres (Ms) co-loaded with dexamethasone and fibronectin (MsDexaFibro). MsDexaFibro were prepared by a water-in-oil-in-water emulsion method including dexamethasone in the organic phase and fibronectin in the inner aqueous phase. To create the chronic glaucoma model, an interventionist and longitudinal animal study was performed using forty-five Long Evans rats (4-week-old). Rats received a single intracameral injection of MsDexafibro suspension (10%w/v) in the right eye. Ophthalmological parameters such as clinical signs, intraocular pressure (IOP), neuro-retinal functionality by electroretinography (ERG), retinal structural analysis by optical coherence tomography (OCT), and histology were evaluated up to six months. According to the results obtained, the model proposed was able to induce IOP increasing in both eyes over the study, higher in the injected eyes up to 6 weeks (p < 0.05), while preserving the ocular surface. OCT quantified progressive neuro-retinal degeneration (mainly in the retinal nerve fiber layer) in both eyes but higher in the injected eye. Ganglion cell functionality decreased in injected eyes, thus smaller amplitudes in PhNR were detected by ERG. In conclusion, a new chronic glaucoma animal model was created by a single injection of MsDexaFibro very similar to open-angle glaucoma occurring in humans. This model would impact in different fields such as ophthalmology, allowing long period of study of this pathology; pharmacology, evaluating the neuroprotective activity of active compounds; and pharmaceutical technology, allowing the correct evaluation of the efficacy of long-term sustained ocular drug delivery systems.

Keywords: Glaucoma animal model; PLGA microspheres; intraocular pressure; multiloaded; neurodegeneration.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Elaboration scheme of dexamethasone-fibronectin co-loaded PLGA microspheres. Created with BioRender.com.
Figure 2.
Figure 2.
Dexamethasone-fibronectin co-loaded PLGA microspheres morphology. Scanning (left and center) and transmission (right) electron microscopy images.
Figure 3.
Figure 3.
Cumulative in vitro release of fibronectin from dexamethasone-fibronectin co-loaded PLGA microspheres.
Figure 4.
Figure 4.
Cumulative in vitro release of dexamethasone from dexamethasone-fibronectin co-loaded PLGA microspheres.
Figure 5.
Figure 5.
Intraocular pressure in the dexamethasone-fibronectin co-loaded microsphere (MsDexaFibro) model. a: Intraocular pressure curve over 6 months. b: Percentage of ocular hypertensive eyes (>20 mmHg). c: Percentage of corticosteroid response and tendency in right eyes over the study. d: Averaged percentage of corticosteroid response in right eyes. Low: <6 mmHg increase; medium: 6–15 mmHg increase; high: >15 mmHg increase. Abbreviations: IOP: intraocular pressure; RE: right eye; LE: left eye; w: week; OHT: ocular hypertension; %: percentage *: p < 0.05; #: p < 0.02 (Bonferroni Correction for multiple comparisons).
Figure 6.
Figure 6.
Neuroretina functionality, measured by dark- and light-adapted electroretinography (ERG), in the dexamethasone-fibronectin co-loaded microspheres (MsDexaFibro) model over 6 months of follow-up. MsDexafibro: microspheres loaded with dexamethasone and fibronectin; RE: right eye; LE: left eye; w: week; DA: dark-adapted; LA: light-adapted; μV: microvolts; ms: milliseconds.
Figure 7.
Figure 7.
A Neuro-retinal thickness in microns by OCT throughout 6-month follow-up. B. Average thickness percentage loss by OCT in microspheres co-loaded with dexamethasone and fibronectin (MsDexaFibro) model up to 6-month follow-up. MsDexaFibro: microspheres co-loaded with dexamethasone and fibronectin; RE: right eye; LE: left eye; OCT: optical coherence tomography; RNFL: Retinal Nerve Fiber Layer; GCL: Ganglion Cell Layer complex; average thickness in microns (μm); w: week; %: percentage.
Figure 8.
Figure 8.
Neuro-retinal loss rate measured by optical coherence tomography (OCT) in the co-loaded with dexamethasone and fibronectin microspheres (MsDexaFibro) model. MsDexaFibro: microspheres co-loaded with dexamethasone and fibronectin; RE: right eye; LE: left eye; w: week; RNFL: Retinal Nerve Fiber Layer; GCL: Ganglion Cell Layer complex.
Figure 9.
Figure 9.
Ganglion cell analysis in glaucomatous eyes. A. Ganglion cells were counted in four areas (squares) of a radial section of the retina passing through the optic nerve. B. Two representative images of the retina marked with anti-Brn3a corresponding to a left non-intervened eye (LE) and a right eye (RE) injected with dexamethasone-fibronectin microspheres from the same animal. The mean number of ganglion cells per linear mm of retina was not different between non-intervened and injected eyes. GCL: Ganglion cell layer; INL: Inner nuclear layer; ONL: Outer nuclear layer. Scale bars: (A) 1 mm, (B) 30 µm.
Figure 10.
Figure 10.
Detection of microspheres in injected eyes. A. Paraffin sections stained with Hematoxylin/Eosin exhibited the presence of the microspheres integrated into the iridocorneal angle (arrowheads), a finding never observed in the control ones. B. The characteristic light diffraction produced by microspheres using Nomarski microscopy (arrowheads) confirmed their presence in the iridocorneal angle of injected eyes. C. The Fluorescent Stain BODIPY (green) also showed the presence of microspheres hampering the iridocorneal angle and the trabecular meshwork. Nuclei were counterstained with Hoechst (blue). LE: left eye (non-intervened); RE: Right eye (dexamethasone-fibronectin microsphere injected). CB: Ciliary body; I: Iris; C: cornea; TM: Transmission mode. Scale bars: 100 µm.
Figure 11.
Figure 11.
Iridocorneal synechias were observed in injected eyes (arrows). A. General view of a synechia between iris and the cornea. B. Using Nomarski microscopy, the diffracted light from the microspheres (arrowheads) was observed between the cornea and iris at the level of the focal contact between them. C. Staining with BODIPY (green) confirmed the presence of microspheres gluing the cornea and iris. Nuclei were counterstained with Hoechst (blue). C: cornea; I: Iris; L: lens; TM: Transmission mode. Scale bars: 100 µm.

Similar articles

Cited by

References

    1. Agarwal R, Agarwal P. (2017). Rodent models of glaucoma and their applicability for drug discovery. Expert Opin Drug Discov 12:261–70. 10.1080/17460441.2017.1281244. - DOI - PubMed
    1. Anderson DR. (2003). Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 14:86–90. - PubMed
    1. Arranz-Romera A, Davis BM, Bravo-Osuna I, et al. (2019). Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. J Control Release 297:26–38. 10.1016/j.jconrel.2019.01.012. - DOI - PubMed
    1. Arranz-Romera A, Esteban-Pérez S, Garcia-Herranz D, et al. (2019). Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases. Drug Discov Today 24:1644–53. - PubMed
    1. Arranz-Romera A, Hernandez M, Checa-Casalengua P, et al. (2021). A safe GDNF and GDNF/BDNF controlled delivery system improves migration in human retinal pigment epithelial cells and survival in retinal ganglion cells: potential usefulness in degenerative retinal pathologies. Pharmaceuticals 14:50. - PMC - PubMed